Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316
Watts, D.H.; Balasubramanian, R.; Maupin, R.T.; Delke, I.; Dorenbaum, A.; Fiore, S.; Newell, M.-L.; Delfraissy, J.-F.; Gelber, R.D.; Mofenson, L.M.; Culnane, M.; Cunningham, C.K.
American Journal of Obstetrics and Gynecology 190(2): 506-516
2004
ISSN/ISBN: 0002-9378 PMID: 14981398 DOI: 10.1016/j.ajog.2003.07.018Document Number: 232682
The purpose of this study was to evaluate rates of maternal toxicity, pregnancy complications, and peripartum morbidity by type and duration of antiretroviral therapy (ART) during pregnancy. The Pediatric AIDS Clinical Trials Group (PACTG) Protocol 316 (PACTG 316) study evaluated the addition of intrapartum/neonatal nevirapine to background ART to reduce perinatal transmission of human immunodeficiency virus-1 (HIV-1). For this secondary analysis, women were categorized into one of six groups on the basis of ART during pregnancy (monotherapy [monoRx], combination without protease inhibitor [PI], combination with PI), and start time (early: before or during first trimester; late: second or third trimester). One thousand four hundred seven women were included: 288 monoRx late, 34 monoRx early, 327 combo, no PI late, 175 combo, no PI early, 320 combo, PI late, and 263 combo, PI early. Symptoms and laboratory abnormalities of moderate grade or more occurred in less than 5% of women. Only gestational diabetes (highest in combo PI early) varied significantly by therapy group. In HIV-infected women receiving prenatal care and ART, adverse events were uncommon.
Document emailed within 0-6 h
